HeartSciences Provides Business Update and Reports First Quarter Fiscal 2023 Financial Results
Provided By Globe Newswire
Last update: Sep 13, 2022
Nearing Completion of Patient Recruitment in
FDA Pivotal Clinical Validation Study of MyoVista®
Remains on Track for MyoVista® FDA De Novo Resubmission in Current Fiscal Year
Read more at globenewswire.com3.49
-0.03 (-0.85%)
NASDAQ:HSCSW (9/18/2025, 8:00:01 PM)
0.0729
-0.01 (-16.97%)
Find more stocks in the Stock Screener
HSCS Latest News and Analysis
